Akoya Biosciences Inc AKYA.OQ AKYA.O is expected to show a rise in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025
The Marlborough Massachusetts-based company is expected to report a 8.7% increase in revenue to $19.949 million from $18.35 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Akoya Biosciences Inc is for a loss of 20 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Akoya Biosciences Inc is $3.00, above its last closing price of $1.10.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.16 | -0.16 | -0.17 | Missed | -4.6 |
Sep. 30 2024 | -0.20 | -0.20 | -0.21 | Missed | -3.1 |
Jun. 30 2024 | -0.27 | -0.27 | -0.27 | Met | -0.8 |
Mar. 31 2024 | -0.29 | -0.29 | -0.48 | Missed | -66.2 |
Dec. 31 2023 | -0.27 | -0.27 | -0.22 | Beat | 18.1 |
Sep. 30 2023 | -0.36 | -0.37 | -0.26 | Beat | 28.9 |
Jun. 30 2023 | -0.43 | -0.44 | -0.46 | Missed | -3.9 |
Mar. 31 2023 | -0.50 | -0.48 | -0.49 | Missed | -1.5 |
This summary was machine generated May 9 at 23:54 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)